| Assessment Status | Rapid Review Complete |
| HTA ID | 25049 |
| Drug | Trastuzumab deruxtecan |
| Brand | Enhertu® |
| Indication | Trastuzumab deruxtecan as monotherapy is indicated for the treatment of adult patients with advanced HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma who have received a prior trastuzumab-based regimen. |
| Assessment Process | |
| Rapid review commissioned | 06/08/2025 |
| Rapid review completed | 03/09/2025 |
| Rapid review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of trastuzumab deruxtecan compared with the current standard of care, on the basis of the proposed price relative to currently available therapies. |
Next steps: The NCPE Assessment Report and recommendation, will be considered by the HSE when making their decision on reimbursement, while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.
Further information on this process may be found here.
Further information on the status of this decision may be found here.